BioCentury
ARTICLE | Clinical News

CV-301: Phase II started

May 5, 2014 7:00 AM UTC

Bavarian Nordic said the NCI began an open-label, U.S. Phase II trial to compare CV-301 plus bacillus Calmette-Guerin (BCG) vs. BCG alone in 54 patients with high-grade non-muscle invasive bladder can...